An experimental new class of drugs is aimed at rendering TGF-beta and CTGF ineffective by blocking their ability to bind with cell receptors.

FORBES: Scar Wars

In the wake of his results Roche have begun testing an old class of experimental anxiety drugs called mGluR5 inhibitors in fragile X patients.

FORBES: The Man Behind Biotech's Bold Push For Autism Drugs

In the wake of his results Roche and Novartis have begun testing an old class of experimental anxiety drugs called mGluR5 inhibitors in fragile X patients.

FORBES: Magazine Article